NCT04679909View on ClinicalTrials.gov

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

December 1, 2021

Study Completion Date

December 21, 2022

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

AdCOVID

Administered intranasally

OTHER

Placebo

Administered intranasally

Trial Locations (6)

20850

Optimal Research, Rockville

32934

Optimal Research, Melbourne

33012

AGA Clinical Trials, Hialeah

61614

Optimal Research, Peoria

78229

Clinical Trials of Texas, San Antonio

78705

Optimal Research, Austin

Sponsors

Lead Sponsor

Altimmune, Inc.
All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY

NCT04679909 - Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) | Biotech Hunter | Biotech Hunter